Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock Pharmaceutical Investing
Bristol Myers Squibb Data at ACR Convergence 2020 Underscore Commitment to Advancing Science for Patients with Difficult-to-Treat Immune-Mediated Diseases Biotech Investing
LYNPARZA® Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
LYNPARZA® in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer Pharmaceutical Investing
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen Pharmaceutical Investing
Bristol Myers Squibb Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla® in Pivotal Phase 3 Psoriasis Study Biotech Investing
